Drugs / RGL-305
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07006012 | Apr 2025 → Mar 2028 expected | lymphoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGL-305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07006012 ↗ |
| Modality | Cell therapy | “all patients would receive RGL-305 cell reinfusion therapy.” NCT07006012 ↗ |
| Route | Intravenous | “RGL-305 is administered intravenously” NCT07006012 ↗ |